Experimental drug offered to fight wasting in advanced pancreatic cancer
NCT ID NCT07399015
Summary
This program provided early access to an investigational drug called mifomelatide for adults with advanced pancreatic cancer who were experiencing severe, unintentional weight loss (cachexia). The goal was to help patients who had no other satisfactory treatment options for this debilitating symptom. Participants received a daily injection for up to 13 weeks while continuing their standard cancer care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PDAC are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.